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OBJECTIVES We investigated whether glutathione (GSH), a reduced thiol that modulates redox state and
forms adducts of nitric oxide (NO), improves endothelium-dependent vasomotion and NO
activity in atherosclerosis.
BACKGROUND Endothelial dysfunction and reduced NO activity are associated with atherosclerosis and its
clinical manifestations such as unstable angina.
METHODS In the femoral circulation of 17 patients with atherosclerosis or its risk factors, endothelium-
dependent vasodilation with acetylcholine (ACH), and endothelium-independent vasodila-
tion with nitroglycerin and sodium nitroprusside were studied before and after GSH. In 10
patients, femoral vein plasma cyclic guanylate monophosphate (cGMP) levels were measured
during an infusion of ACH before and after GSH. Femoral artery flow velocity was measured
using a Doppler flow wire and the resistance index (FVRI) calculated as mean arterial
pressure 4 flow velocity.
RESULTS Glutathione strongly potentiated ACH-mediated vasodilation; at the two doses, FVRI
decreased by 47% and 56% before, and by 61% and 67% after GSH (p 5 0.003). Glutathione
also elevated cGMP levels in the femoral vein during ACH infusion from 17.6 6 3 to 23.3 6
3 pmol/ml (p 5 0.006). Augmentation of ACH responses was only observed in patients with
depressed endothelial function. Glutathione did not influence endothelium-independent
vasodilation with either NO donor.
CONCLUSIONS Thiol supplementation with GSH selectively improves human endothelial dysfunction by
enhancing NO activity. (J Am Coll Cardiol 1999;34:507–14) © 1999 by the American
College of Cardiology
The endothelium, through the release of nitric oxide (NO),
is central to the regulation of a variety of vascular functions
including vasomotion, lipid transport and hemostasis (1).
Abnormal function of endothelial cells is associated with
reduced NO bioavailability, and is believed to be an early
event in the pathogenesis of atherosclerosis (2). Though the
exact mechanism leading to the reduction in NO activity
remains unknown, extensive evidence from in vitro studies
suggests that atherosclerosis and its risk factors such as
hypercholesterolemia, hypertension and diabetes lead to
increased generation of oxygen free radicals capable of
degrading NO (3–5). Diminished NO activity enhances the
expression of transcription factor–nuclear factor kappa B
(6), which up-regulates the synthesis of inflammatory me-
diators such as cytokines and adhesion molecules. Further-
more, at sites of advanced atherosclerotic lesions, reduced
NO activity predisposes to abnormal vasomotion, and to
thrombus formation (by increasing platelet adhesion and
aggregation). Thus, reversing endothelial dysfunction and
improving NO bioavailability may be effective in treating
ischemia by improving vasomotion, reducing thrombotic
cardiovascular events and modifying the progression of
atherogenesis.
Endogenous thiols, compounds with a sulfhydryl group
(SH), form stable, biologically active adducts with NO in
several human biologic systems (7). These S-nitrosothiols
have half-lives considerably longer than that of NO,
strongly activate guanylate cyclase and seem to be important
intermediates in the action of NO (8). Though the precise
cellular mechanisms remain unclear, it is likely that these
S-nitrosothiols improve cytoplasmic and transmembrane
transport of NO from the endothelium to vascular smooth
muscle cells and platelets. Proteins, in particular albumin,
are the major thiol in plasma; glutathione (GSH) serves as
an important intracellular thiol (7,9,10). Glutathione also
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plays an important role in cell defense by virtue of its
antioxidant property (7). Glutathione-related antioxidant
defenses have been shown to be relatively deficient in
atherosclerotic plaques (11). Furthermore, male adolescents
with a family history of premature coronary artery disease
have depressed plasma GSH levels (12). Depletion of
plasma and vascular GSH may result from increased oxida-
tive stress and contribute to the pathogenesis of atheroscle-
rosis (13). On the basis of the recent experimental studies
demonstrating that exogenous reduced thiols potentiate the
vasodilator (14) and antiplatelet (15,16) effects of NO, we
hypothesized that thiol supplementation with GSH would
improve endothelial dysfunction and NO bioavailability in
patients with atherosclerosis or its risk factors. To obtain
insights into the mechanisms underlying any improvement
in endothelial function with GSH, we also studied the
effects of GSH on the NO donors nitroglycerin and sodium
nitroprusside, which release NO by thiol-dependent and
-independent pathways in the circulation.
METHODS
Patients
We studied 17 patients, 13 with atherosclerosis of the
coronary artery and/or the iliofemoral circulation, four
without angiographic atherosclerosis but with one or more
risk factor (arterial pressure .140/90 mm Hg, cholesterol
.200 mg/dl, presence of diabetes, age .60 years or history
of current or recent smoking), who were undergoing diag-
nostic cardiac catheterization for investigation of chest pain
or abnormal noninvasive tests. Patients with recent myocar-
dial infarction, valvular heart disease, or occlusive peripheral
vascular disease were excluded. The mean age was 56 6 9
years (mean 6 SD); 10 (59 %) were male, 7 were hyper-
tensive, hypercholesterolemia was present in 14 patients, 4
were either current smokers or had smoked in the previous
year, 5 had diabetes and 5 were older than 60 years of age.
Protocol
All cardiac medications were withdrawn at least 48 h before
the study, and aspirin or other cyclooxygenase inhibitors
were discontinued seven days before. The study was ap-
proved by the National Heart, Lung, and Blood Institute
Investigational Review Board, and informed consent was
obtained from all patients. A 6-F multipurpose A2 (Cordis,
Miami, Florida) catheter was introduced retrogradely 1 cm
beyond the end of a 7-F femoral artery sheath. A 0.018-in.
(0.046-cm) Doppler flow wire (Cardiometrics, Mountain
View, California) was introduced through the catheter and
positioned 1 cm beyond the catheter tip to obtain an adequate
flow velocity signal. All drugs were infused through the
catheter 1 to 2 cm below the tip of the Doppler wire. A femoral
angiogram was performed to assist with positioning of the wire
and to visualize obstructive atherosclerotic plaques in the
iliofemoral circulation, which may compromise blood flow
measurements. Since diameter measurements were not
made at the level of the Doppler wire with each interven-
tion, we calculated femoral vascular resistance index (FVRI)
as the mean arterial pressure 4 femoral blood flow velocity.
Study 1: Effect of GSH on Endothelium-Dependent and
-Independent Vasodilation
After measurement of baseline flow velocity and mean
arterial pressure, endothelium-dependent vasodilation was
estimated by performing a dose–response curve with incre-
mental infusions of acetylcholine (ACH) at 150 and
300 mg/min for 2 min each. Endothelium-independent
function was estimated with two NO donors: nitroglycerin
(NTG) at 25 mg/min for 3 min and sodium nitroprusside at
20 mg/min for 2 min (Fig. 1).
In 15 patients, after a 5-min recovery period, GSH (Sigma,
St Louis, Missouri), a reduced thiol, was infused intra-arterially
at 50 mg/min for 10 min to achieve an estimated concentration
of 1 mmol/liter. While continuing the infusion of GSH at
50 mg/min, ACH was coinfused at 150 mg/min and at
300 mg/min for 2 min each. After a 10-min recovery period,
the GSH infusion was continued and coinfused with NTG at
25 mg/min for 3 min and sodium nitroprusside at 20 mg/min
for 2 min. Blood flow velocity and mean arterial pressure were
measured after each intervention.
Reproducibility. Reproducibility of the microvascular di-
lator response to repeated infusions of ACH and sodium
nitroprusside was tested in six patients during infusion of
5% dextrose. The FVRIs during the first and second
infusions were as follows: ACH (150 mg/min), 3.5 6 0.6
and 4.0 6 0.6, p 5 0.2 (coefficient of variation [CV]
17.2%); ACH (300 mg/min), 3.1 6 0.5 and 3.7 6 0.6, p 5
0.2 (CV 8.2%); sodium nitroprusside, 1.8 6 0.1 and 1.8 6
0.2, p 5 0.7 (CV 8.7%). These findings are consistent with
our previously described reproducibility of vascular re-
sponses in the femoral circulation (17).
Study 2: Effect of GSH on Endothelium-Derived NO
In 10 patients, femoral vein plasma cyclic guanosine mono-
phosphate (cGMP) levels were measured as an indirect
assay of NO. Measurements were made at baseline and
during the infusion of ACH (300 mg/min), before and after
GSH. After an intravenous loading dose of 15 mg/kg over
5 min, the infusion was continued at a rate of 60 mg/kg over
Abbreviations and Acronyms
ACH 5 acetylcholine
ANOVA 5 analysis of variance
cGMP 5 cyclic guanosine monophosphate
CV 5 coefficient of variation
FVRI 5 femoral vascular resistance index
GSH 5 glutathione
NO 5 nitric oxide
NTG 5 nitroglycerin
SH 5 sulfhydryl group
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30 min to produce an approximate systemic plasma concen-
tration of 0.25 mmol/liter (Fig. 1). As before, GSH was also
infused directly into the femoral artery at the reduced rate of
37.5 mg/min during the last 10 min of the intravenous
infusion. This combined regime of intravenous and intra-
arterial GSH was estimated to produce a femoral artery
plasma concentration of 1 mmol/liter. While continuing the
GSH infusions, ACH (300 mg/min) was coinfused as
described above (Fig. 1). Flow velocity measurements were
made, and blood was collected from the femoral vein at
baseline, and after ACH, before and after GSH, to deter-
mine cGMP concentration.
Measurement of plasma cGMP. Nine milliliters of blood
was drawn into syringes containing 1 ml sodium citrate
(final concentration 14.7 mmol/liter) and the specific
cGMP phosphodiesterase inhibitor zaprinast (final concen-
tration 10-5 mol/liter). Within 1 min of sampling, the blood
was centrifuged at 140 g for 10 min. To two 1-ml aliquots
of the resultant plasma, ice-cold 6% trichloroacetic acid was
added to extract the cGMP. After neutralization by solvent
partition with a mixture of Freon and tri-n-octylamine,
cGMP was measured by radioimmunoassay (RPA 525,
Amersham International, Chicago, Illinois).
Reproducibility. In four patients, reproducibility of arterial
and venous plasma cGMP levels was tested during infusions
of 5% dextrose and ACH (300 mg/min) twice in each
patient. There was no difference between the femoral
arterial and venous plasma cGMP levels under resting
conditions (23.5 6 3 and 24.8 6 2.7 pmol/ml, p 5 0.4,
respectively, CV 17.5%). Similarly, there was no change in
arterial cGMP content during infusion of ACH (22.5 6 3
before and 21.4 6 1 pmol/ml, p 5 0.7 during ACH, CV
12%). Therefore, in the 10 study patients, only venous
plasma cGMP content was measured.
Statistical Analysis
Data are expressed as mean 6 SEM. Differences between
means were compared by paired or unpaired Student t test,
as appropriate. The effect of GSH on the ACH responses
was compared by a two-way repeated measures analysis of
variance (ANOVA) with appropriate interactions. All p
values were two tailed, and a value ,0.05 was considered of
statistical significance. Correlation analysis was performed
using Pearson correlation coefficient. Although percentage
change in flow velocity and FVRI were calculated, except for
the Pearson correlation, all statistical analyses were per-
formed using absolute values.
RESULTS
Study 1: Femoral Vascular Response to GSH
After 10 min of intra-arterial GSH infusion there was a
trend toward a reduction in vascular resistance (change in
FVRI: 5.8 6 0.4 to 5.4 6 0.4 mm Hgzcm-1zs, p 5 0.07), but
there was no change in flow velocity (18.3 6 1.5 to 19.4 6
1.6, p 5 0.14) or mean arterial blood pressure (99 6
4 mm Hg before and after, p 5 0.9).
Effect of GSH on ACH responses. Acetylcholine infu-
sions produced graded femoral microvascular dilation; at the
two doses (150 and 300 mg/min), flow velocity increased by
97 6 17% and 142 6 22% and FVRI decreased by 47 6 4%
and 56 6 4%, respectively. When coinfused with GSH,
there was significant potentiation of ACH-induced vasodi-
lation; flow velocity increased by 161 6 23% and 197 6
17% (p 5 0.0016, ANOVA) and FVRI decreased by 61 6
3% and 67 6 2% (p 5 0.005, ANOVA) respectively at the
two doses (Fig. 2).
There was a significant negative correlation between the
Figure 1. Protocol design. IA 5 intra-arterially; IV 5 intravenously; D5W 5 5% dextrose.
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patient’s endothelial function measured as the decrease in
FVRI with ACH (300 mg/min) at baseline, and the
magnitude of improvement of ACH response with GSH
(r 5 20.81, p , 0.001), indicating that patients with a
depressed dilator response with ACH had greater improve-
ment with thiol supplementation. We therefore examined
the effect of GSH on the ACH responses in patients whose
endothelial function was within the range (mean 6 2 SD) of
changes observed in normal volunteers and those whose
responses were below this level. In a previous study, normal
subjects without risk factors for atherosclerosis had a 68 6
6.5% reduction in FVRI with 300 mg/min ACH (18). Thus,
eight patients with ACH-mediated reduction in FVRI
.55% were considered to be within the “normal” range, and
the remaining seven patients with FVRI decrease ,55%
were examined as a group with “depressed endothelial
function” (Fig. 3). Significant improvement in ACH-
mediated femoral microvascular vasodilation with GSH was
only apparent in patients with depressed endothelium-
dependent vasodilation (p 5 0.003 for change in FVRI by
ANOVA) (Fig. 3). In contrast, patients with “normal”
endothelial function had no significant change (Fig. 3).
Effect of GSH on the response to NTG and sodium
nitroprusside. Nitroglycerin increased femoral flow veloc-
ity by 41 6 6% and reduced FVRI by 30 6 3% compared
with baseline (p , 0.001, both). After GSH, the 42 6 6%
increase in flow velocity and 33 6 3% reduction in FVRI
were not significantly different (Fig. 4). Sodium nitroprus-
side increased femoral flow velocity by 127 6 14% and
reduced FVRI by 58 6 3% compared with baseline (p ,
0.001, both). After GSH, the 120 6 12% increase in flow
velocity and 59 6 3% reduction in FVRI were not signifi-
cantly different (Fig. 4). Thus, GSH did not potentiate
vasodilation in response to either NO donor.
Study 2: Effect of GSH on Plasma cGMP
The vasodilator responses to ACH during the infusion of
intra-arterial GSH alone and during the combined intrave-
nous and intra-arterial infusions were similar. In the 10
patients who had the combined infusion of GSH in study 2,
baseline FVRI was 6.1 6 0.3 and remained unaltered by
GSH. Acetylcholine (150 and 300 mg/min) reduced FVRI
by 51 6 7% and 59 6 5% before and by 61 6 4% and 65 6
4%, respectively, after GSH (p 5 0.04, ANOVA).
Glutathione did not alter basal venous plasma cGMP
concentration (18.6 6 3.2 to 19.9 6 2.9 pmol/ml, p 5 0.5,
baseline vs. after GSH). However, it strongly potentiated
plasma cGMP level during infusion of ACH (300 mg/min);
femoral vein plasma cGMP level increased by 20.7 6 12%
from 17.6 6 3.2 to 23.3 6 3.2 pmol/ml (p 5 0.006). The
magnitude of increase in venous cGMP level correlated with
the magnitude of improvement in vasodilation with ACH
(measured as the percentage change in FVRI with ACH
before vs. after GSH) (r 5 20.68, p 5 0.032). Thus,
patients with greater improvement in dilation with ACH
after GSH also had a greater increase in plasma cGMP.
DISCUSSION
We have previously shown that endothelial dysfunction,
present in both the coronary and peripheral circulations of
patients with atherosclerosis or its risk factors, is accompa-
nied by a reduction in basal and stimulated activity of NO
(19–21) and is likely to be responsible, at least in part, for
the abnormal vasomotion that accompanies atherosclerosis
(18,22,23). Thus, pharmacologic interventions that reverse
endothelial dysfunction and enhance NO activity may be of
therapeutic value in ischemic syndromes by reducing vaso-
constriction and inhibiting platelet activity. An even more
attractive possibility is that such therapy may prevent
atherogenesis or inhibit its progression if used early in the
disease process. In this study, we have demonstrated that
acute administration of GSH improves endothelial dysfunc-
tion in patients with atherosclerosis or its risk factors by
enhancing NO activity but without augmenting the vaso-
dilator action of the NO donors, NTG and sodium nitro-
prusside.
Effect of GSH on endothelial function and endogenous
NO activity. Previously, we have shown that femoral
microvascular dilation to ACH is endothelium-dependent
and predominantly NO-mediated (18). In the present
study, microvascular dilation with ACH was undoubtedly
enhanced by GSH, a finding that is consistent with a recent
Figure 2. Effects of acetylcholine on femoral blood flow velocity
and femoral vascular resistance index, before and after glutathione.
Data represent mean 6 SEM; p values represent results of
two-way analysis of variance.
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report demonstrating that GSH also improves abnormal
ACH responses in epicardial coronary arteries of patients
with risk factors for atherosclerosis (24). The beneficial
effect of GSH appeared to be restricted to patients with
worse endothelial dysfunction demonstrable as a lower
vasodilator response to ACH, and is consistent with a
previous study in normal volunteers in whom exogenous
N-acetylcysteine did not potentiate endothelium-dependent
vasodilation (25).
Although ACH stimulates release of other relaxing fac-
Figure 3. Effects of acetylcholine on flow velocity and femoral vascular resistance index in patients with normal (left) and depressed
(right) endothelial function, before and after glutathione. Data represent mean 6 SEM; p values represent results of two-way
analysis of variance.
Figure 4. Effects of nitroglycerin (NTG) and sodium nitroprusside on femoral blood flow velocity and femoral vascular resistance index,
before and after glutathione. Data represent mean 6 SEM.
511JACC Vol. 34, No. 2, 1999 Prasad et al.
August 1999:507–14 Thiols and Human Endothelial Dysfunction
tors such as endothelium-derived hyperpolarizing factor and
prostacyclin in addition to NO, only NO increases soluble
cGMP in the vascular wall and platelets. The significant
increase in venous plasma cGMP with ACH and GSH in
our study, with a higher increase in patients with a greater
potentiation of ACH-mediated smooth muscle dilation,
confirms enhancement of the NO pathway with GSH in
patients with endothelial dysfunction.
Nitric oxide–stimulated plasma cGMP may originate
from both platelets and the vessel wall. We designed the
second study with the aim of increasing femoral vascular
and circulating platelet GSH levels. Although the intra-
arterial GSH infusion would be expected to elevate local
femoral plasma concentrations of GSH, systemic levels
would not have changed significantly. Consequently, plate-
lets outside of the femoral circulation would not be exposed
to high levels of GSH, and the rapid transit through the
femoral circulation would also be inadequate to achieve a
steady state. Therefore, we also infused GSH intravenously
to ensure that the circulating platelets were adequately
exposed to exogenous GSH.
Potential mechanisms underlying the improvement in
NO bioavailability. At least two mechanisms may be
potentially responsible for the observed beneficial effects of
GSH on the endothelial function. First, it may enhance the
bioavailability of NO by forming a stable, biologically active
S-nitrosoglutathione adduct (10). Although NO has a very
short half-life, on the order of 0.1 to 1 s, recent evidence
suggests that it circulates in the plasma primarily as
S-nitrosoalbumin after reacting with the SH of cysteine 34
(26), and in red blood cells as nitrosyl-hemoglobin and
S-nitrosohemoglobin. S-Nitrosoalbumin is biologically ac-
tive but has minimal intracellular access and probably serves
as a circulating reservoir of NO (9,16). Low molecular
weight thiols such as cysteine form less diffusion-limited
NO adducts that may transport NO to target sites within
vascular smooth muscle cells and platelets (10). Glutathione
is the major intracellular nonprotein source of the SHs, with
tissue levels ranging between 0.5 and 10 mmol/liter, and is
synthesized intracellularly from cysteine, glutamate and
glycine. It is continuously and irreversibly transported out of
cells to augment extracellular thiol availability. Glutathione
is metabolized by the membrane-bound enzyme gamma-
glutamyl transpeptidase, present in abundant amounts on
endothelial cells, to release cysteine. As cysteine is rapidly
metabolized, GSH acts as the storage and transport form of
cysteine (27).
The second potential mechanism for the action of GSH
may relate to its antioxidant properties (7,28). Experimental
studies suggest that atherosclerosis, hypertension, hypercho-
lesterolemia and diabetes result in increased vascular gener-
ation of oxygen free radicals (3–5). Similarly, increased
oxidative stress has been detected in the plasma of smokers
(29). These oxygen free radicals are capable of inactivating
NO and inducing endothelial dysfunction. Because GSH
itself is not transported intracellularly, exogenously admin-
istered GSH in this study is most likely to have acted by
supplementing plasma GSH levels to reduce luminal oxi-
dant stress, and thereby increase NO bioavailability in
patients with endothelial dysfunction.
Glutathione and NO donors. Nitroglycerin requires en-
zymatic metabolism in the presence of SH-containing
compounds to release NO. Recent studies indicate that the
enzyme responsible for metabolizing NTG is localized
mainly in the cell membrane fraction of vascular smooth
muscle cells (30). Thus, exogenously administered thiols
would need to elevate vascular interstitial levels to potentiate
NTG. In our study, NTG-mediated microvascular vasodi-
lation was not potentiated by GSH. This is consistent with
the observation in vitro that exogenous GSH does not
potentiate NTG-mediated microvascular dilation in canine
coronary arteries (31). Though GSH is a major source of the
SH radical, exogenous GSH cannot be transported intra-
cellularly and is thus unlikely to acutely influence NTG
responses (26). However, as mentioned above, GSH does
elevate levels of plasma cysteine, which can be transported
intracellularly, but the relatively short infusions used in this
study may have been insufficient to raise cysteine levels in
the vascular interstitium, the site at which NO is generated
from NTG. In contrast, N-acetylcysteine, a pharmacologic
precursor of cysteine, potentiates NTG-mediated vasodila-
tion in the canine coronary circulation, and in human
peripheral and coronary circulations (32–35). Unlike GSH,
N-acetylcysteine can be rapidly transported into the vascular
tissue and generate GSH, possibly accounting for the
observed difference between the two thiols.
In vitro studies have shown that sodium nitroprusside
releases NO by an endothelium-independent mechanism in
the presence of a variety of reducing agents present in
plasma and tissue extracts (36,37). These include thiols such
as cysteine and GSH. However, our study demonstrates that
GSH does not augment sodium nitroprusside–mediated
peripheral microvascular dilation in vivo. Although this may
be explained by the poor vascular permeability of GSH, a
previous study in humans showed that N-acetylcysteine also
does not potentiate the systemic or pulmonary hemody-
namic effects of sodium nitroprusside (38). These data
suggest that thiols are not rate-limiting, perhaps due to the
availability of other reducing agents, in the peripheral
vasodilator activity of sodium nitroprusside in patients with
atherosclerosis or its risk factors. Alternatively, any poten-
tiation of NO release from nitroprusside by GSH in the
blood may have been obscured by binding of NO to reduced
hemoglobin (36).
Study limitations. We have not studied normal volunteers
without risk factors for atherosclerosis in this study and
therefore cannot comment on whether the observed im-
provement in patients would be present in normal subjects.
However, the improvement in ACH-mediated vasodilation
and plasma cGMP levels observed in patients with endo-
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thelial dysfunction, and the finding that those with ACH-
mediated dilation within the range observed in normal
subjects had no improvement, suggest that the effect of
GSH is likely to be observed in those in whom stimulated
NO activity is most compromised. It is also unlikely that the
greater improvement observed in patients with the worst
baseline function is artifactual, because measurements of
increase in cGMP levels, which provided an independent
index of luminal NO release, were also greater in this subset.
Plasma cGMP elevation with GSH after ACH compared
with ACH alone confirmed increased production of NO,
but we are unable to measure the contribution of platelets
versus the vascular wall to the observed enhancement
because the NO pathway is active in both. Recent studies
demonstrating potent inhibition of platelets with
S-nitrosoglutathione (39,40) suggest that GSH-induced
increase in plasma cGMP is a reflection also of its potential
antiplatelet aggregative action.
Conclusions and implications. In this study, we demon-
strate that depressed peripheral vascular endothelium-
dependent vasodilation, present in patients with atheroscle-
rosis and those with its risk factors, is selectively improved
by GSH. The observation that NO bioavailability is en-
hanced offers a potential cellular mechanism by which thiol
supplementation may be of clinical benefit. This acute
improvement in endothelial function, and the recent dem-
onstration that S-nitrosoglutathione has platelet inhibitory
effects in humans, indicate that thiols such as GSH and
cysteine may have therapeutic potential (39,40). In a previ-
ous randomized double-blind study, the combination of
NTG and N-acetylcysteine significantly reduced the inci-
dence of myocardial infarction compared with NTG alone
in patients with severe unstable angina (41). Furthermore,
an inhibitory effect of S-nitrosoalbumin on neointimal
proliferation in an animal model of vascular injury suggests
that long-acting NO adducts may also have the potential to
prevent restenosis after angioplasty (42) and retard progres-
sion of atherosclerosis. However, GSH is completely me-
tabolized by intestinal and hepatic gamma glutaryl trans-
ferase and is therefore unsuitable for oral therapy. L-2-
Oxothiazolidine-4-carboxylic acid, a cysteine prodrug, can
be administered orally and repletes cellular glutathione
levels. Data from a double-blind placebo-controlled study
suggests that L-2-oxothiazolidine-4-carboxylic acid acutely
improves flow-mediated endothelium-dependent brachial
artery vasodilation in patients with coronary artery disease
(43), and suggests that thiols may have antiatherogenic
properties. However, further studies are required to estab-
lish their mechanism of action and clinical efficacy.
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